NCT06215677

Neoadjuvant Immunotherapy for T4 dMMR Colon Cancer

Efficacy of Neoadjuvant Immunotherapy for T4 Deficient Mismatch Repair (dMMR) Colon Cancer: A Prospective, Single-arm, Phase Ⅱ Clinical Trial

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 18 (estimated)
• Sponsor: Peking Union Medical College Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Due to dMMR colon cancer patients respond poorly to conventional chemotherapy, but immunotherapy can significantly improve the pCR in this group of patients, this study intends to explore whether neoadjuvant immunotherapy can improve the R0 resection rate with preservation of adjacent organs in T4 colon cancer patients with dMMR.

Conditions

• Colon Cancer
• Mismatch Repair Deficiency
• Immunotherapy

Interventions

Type	Name	Description
DRUG	Camrelizumab	Camrelizumab 200mg for 3 cycles. Patients will undergo surgery 2-3 weeks after the last cycle of immunotherapy, type and extent of the surgery will be selected by the surgeon.

Timeline

• Start date: 2024-01-01
• Primary completion: 2025-05-10
• Completion: 2030-02-10
• First posted: 2024-01-22
• Last updated: 2025-09-05

Locations

2 sites across 1 country: China